Market Overview

UPDATE: Citigroup Reiterates Neutral Rating, Raises PT for Boston Scientific

Share:
Related BSX
Boston Scientific Initiates Global Study To Assess EMBLEM Subcutaneous Implantable Defibrillator In Primary Prevention Patients With Low Ejection Fraction
New Data Demonstrate Greater Pain Relief With Boston Scientific Precision Spectra™ Spinal Cord Stimulator System

In a company update published earlier today, Citigroup Inc. reiterated its Neutral rating for the Boston Scientific Corporation (NYSE: BSX) and slightly raised its price target from $6.30 to $6.50.

Citigroup went on to say “In March 2004, Boston Scientific entered an unprecedented new product cycle for a large-capital medical technology company with the U.S. launch of the TAXUS stent. In an attempt to offset a slowing growth profile, Boston Scientific made a bold bid to acquire Guidant for $80 per share. Boston significantly overpaid for Guidant, which has led to significant earnings dilution and a high debt load, in our view. More recently, a slow recovery for the ICD business and launch of next-generation Promus drug-eluting stent have pressured gross margins, which should only abate when the in-house manufactured Promus Element reaches the US in mid-2012. Liquidity issues remain an overhang with significant debt overhang and unsettled legal issues.”

Boston Scientific Corporation closed yesterday at $6.31.

Latest Ratings for BSX

DateFirmActionFromTo
Apr 2015BarclaysMaintainsOverweight
Apr 2015Leerink SwannMaintainsOutperform
Apr 2015RBC CapitalMaintainsOutperform

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Citigroup Inc.Analyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (BSX)

Around the Web, We're Loving...

Get Benzinga's Newsletters